• c-Myc tag peptide: Assay Workflow & Troubleshooting

  2026-08-13

  Use the c-Myc tag peptide as a defined competitive reagent for antibody-binding studies, immunoassay specificity controls, and selective elution of tagged fusion proteins. This workflow also shows how to connect tag-dependent measurements with transcription-factor stability studies without confusing an assay reagent with a cellular c-MYC inhibitor.

• Patient-Derived Gastric Cancer Assembloids

  2026-08-13

  Shapira-Netanelov and colleagues developed a patient-derived gastric cancer assembloid that combines matched tumor organoids with stromal subpopulations from the same tumor. The model reproduced tumor–stroma-associated transcriptional changes and revealed that stromal composition can substantially alter drug sensitivity, supporting more physiologically relevant personalized treatment studies.

• E-64 and Cathepsins in Salt-Sensitive Hypertension

  2026-08-12

  Blass and colleagues tested chronic broad cysteine cathepsin inhibition in Dahl salt-sensitive rats, combining high-salt hypertension with E-64 infusion, podocyte calcium imaging, and protein analysis. E-64 did not prevent hypertension, albuminuria, kidney damage, or altered basal podocyte calcium under the experimental conditions, providing an important negative result for interpreting cathepsin biology in renal disease.

• Selective Autophagy Tunes IRF3 and Type I IFN

  2026-08-12

  Wu and colleagues show that CALCOCO2/NDP52-mediated selective autophagy controls IRF3 stability according to viral burden, while PSMD14 preserves IRF3 by removing K27-linked ubiquitin chains at lysine 313. The work defines a regulatory axis that limits excessive antiviral signaling without eliminating the basal IRF3 required for type I interferon production.

• Deferiprone: Iron Stress to Translational Strategy

  2026-08-11

  Deferiprone, or 3-hydroxy-1,2-dimethylpyridin-4-one, is more than an iron-chelating reagent: it is a controllable perturbation tool for connecting iron availability with metabolism, proliferation, inflammation, and oxidative stress. This thought-leadership guide translates recent enterocyte findings into practical strategies for cancer biology, vascular research, and translational assay design.

• CUDC-907 Protocol and QC Guide

  2026-08-11

  CUDC-907 (SKU A4097) is a dual PI3K and HDAC inhibitor for controlled studies of PI3K/AKT signaling, histone acetylation, cell-cycle progression, and apoptosis in cancer research models. This dossier-guided article provides formulation, treatment, readout, and quality-control practices for in vitro work; the compound is not intended for diagnostic, therapeutic, or clinical use.

• Berberine, SIRT6-AMPK, and Atrial Fibrillation

  2026-08-10

  The reference study identifies SIRT6-AMPK signaling as a protective mechanism against angiotensin II-induced atrial remodeling and atrial fibrillation susceptibility. Using human atrial evidence, bioinformatics, a murine model, and SIRT6 gain- and loss-of-function experiments, it links berberine activity to suppression of NLRP3 inflammasome signaling and oxidative injury.

• EZ Cap™ Cy5 EGFP mRNA: Assay Design

  2026-08-09

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) enables a two-axis view of mRNA delivery: Cy5 reports intracellular mRNA-associated fluorescence, while EGFP reports productive translation. This guide translates recent LNP biophysical findings into practical assay design, controls, and interpretation strategies.

• LLC-PK1-MDR1 Model for BBB Permeability Screening

  2026-08-08

  Hu and colleagues developed a Transwell blood-brain barrier surrogate based on LLC-PK1-MOCK/MDR1 cells and combined permeability testing with correction for lysosomal trapping. Across 41 compounds, the model correlated well with unbound brain distribution and provided a practical framework for prioritizing CNS drug candidates before extensive in vivo studies.

• 3X (DYKDDDDK) Peptide for Reliable Cell Assays

  2026-08-07

  This scenario-driven guide explains how 3X (DYKDDDDK) Peptide, SKU A6001, can strengthen upstream protein-validation steps in cell viability, proliferation, and cytotoxicity workflows. It covers epitope exposure, metal sensitivity, handling, interpretation, and practical vendor selection without treating the peptide as a direct viability reagent.

• Epoxomicin in Proteostasis: Precision Tools for ER Stress an

  2026-08-07

  Explore how Epoxomicin, a potent proteasome inhibitor, advances research into protein quality control, ER stress, and disease mechanisms. This article uniquely connects mechanistic insight to real-world assay design, providing actionable guidance for scientists.

• Structure-Based Discovery of SARS-CoV-2 NSP15 Inhibitors

  2026-08-06

  This study employs structure-based virtual screening to identify thymopentin and oleuropein as potent inhibitors of the NSP15 endoribonuclease in SARS-CoV-2. The findings highlight the therapeutic potential of targeting NSP15 to disrupt viral immune evasion, providing a rational framework for future antiviral strategies.

• Tetrahydromagnolol: Unraveling CB2 Agonism in Cancer Metasta

  2026-08-06

  Explore how Tetrahydromagnolol, a potent peripheral CB2 receptor agonist, offers unique mechanistic insights for metastasis and inflammation models. This article provides a deep scientific analysis connecting cannabinoid signaling to cytoskeletal remodeling in cancer.

• MG-132 (Z-LLL-al): Proteasome Inhibition, Redox Balance, and

  2026-08-05

  Explore how MG-132, a potent proteasome inhibitor, enables advanced apoptosis assays and cell cycle arrest studies. This article uniquely bridges redox biology, autophagy modulation, and translational insight for cancer and respiratory research.

• Nicotine’s Role in Chronic Kidney Disease Progression: Mecha

  2026-08-05

  This article synthesizes key findings from Jain and Jaimes (2013), highlighting how nicotine signaling through non-neuronal nAChRs exacerbates chronic kidney disease (CKD) progression in smokers. Mechanistic insights into oxidative stress and pro-fibrotic pathways are discussed, with implications for translational research targeting vascular and fibrotic components of CKD.

16904 records 1/1127 page Next 12345 下5页 Last page